- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: May 2019
- Public Summary Document (PSD) May 2019 PBAC Meeting - PDF
- Public Summary Document (PSD) May 2019 PBAC Meeting - Word
Bevacizumab – May 2019
Bevacizumab: Solution for intravenous infusion, 100 mg in 4 mL, 400 mg in 16 mL; Avastin®
Last updated
1 November 2019